Protagenic Therapeutics (PTIX) versus The Competition Head to Head Comparison

Protagenic Therapeutics (NASDAQ:PTIX) is one of 968 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Protagenic Therapeutics to related businesses based on the strength of its dividends, analyst recommendations, valuation, institutional ownership, earnings, risk and profitability.

Risk & Volatility

Protagenic Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Protagenic Therapeutics’ competitors have a beta of 0.84, indicating that their average stock price is 16% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Protagenic Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagenic Therapeutics	0	0	0	0	N/A
Protagenic Therapeutics Competitors	5936	17803	43170	880	2.58

As a group, “Pharmaceutical preparations” companies have a potential upside of 86.62%. Given Protagenic Therapeutics’ competitors higher probable upside, analysts plainly believe Protagenic Therapeutics has less favorable growth aspects than its competitors.

Profitability

This table compares Protagenic Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protagenic Therapeutics	N/A	-101.81%	-82.18%
Protagenic Therapeutics Competitors	-2,638.22%	-226.71%	-28.57%

Institutional and Insider Ownership

8.0% of Protagenic Therapeutics shares are held by institutional investors. Comparatively, 44.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 37.0% of Protagenic Therapeutics shares are held by insiders. Comparatively, 14.5% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Protagenic Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Protagenic Therapeutics	N/A	-$5.00 million	-1.12
Protagenic Therapeutics Competitors	$1.59 billion	$140.37 million	-4.49

Protagenic Therapeutics’ competitors have higher revenue and earnings than Protagenic Therapeutics. Protagenic Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Protagenic Therapeutics competitors beat Protagenic Therapeutics on 6 of the 10 factors compared.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.